ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	89.15	0.03	1.32	5.51	17.84
Revenue Growth (YoY)	297063.33%	-97.72%	-76.10%	-69.13%	-
Cost of Revenue	20.56	20.27	17.12	20.27	14.07
Gross Profit	68.59	-20.24	-15.8	-14.77	3.77
Selling, General & Admin	71.68	47.28	18.66	4.69	4.23
Operating Expenses	71.68	47.28	18.66	4.69	4.23
Operating Income	-3.08	-67.52	-34.46	-19.45	-0.47
Interest Expense	-	-	-	-0.8	-0.4
Currency Exchange Gain (Loss)	-	-	-	-	-0.2
Other Non Operating Income (Expenses)	4.12	6.01	1.12	0.01	0
EBT Excluding Unusual Items	1.03	-61.51	-33.34	-20.24	-1.07
Gain (Loss) on Sale of Investments	7.25	6.85	-0.29	-	-
Gain (Loss) on Sale of Assets	-	0.3	-	-	-
Pretax Income	8.29	-54.37	-34.68	-20.24	-1.07
Income Tax Expense	0.29	-	-	-	-
Net Income	8	-54.37	-34.68	-20.24	-1.07
Net Income to Common	8	-54.37	-34.68	-20.24	-1.07
Shares Outstanding (Basic)	97	95	40	29	20
Shares Outstanding (Diluted)	102	95	40	29	20
Shares Change (YoY)	7.54%	138.30%	38.39%	42.81%	-
EPS (Basic)	0.08	-0.57	-0.87	-0.70	-0.05
EPS (Diluted)	0.08	-0.57	-0.87	-0.70	-0.05
Free Cash Flow	12.99	-59.44	-40.28	-17.62	9.07
Free Cash Flow Per Share	0.13	-0.62	-1.01	-0.61	0.45
Gross Margin	76.94%	-	-	-268.20%	21.11%
Operating Margin	-3.46%	-225066.67%	-2618.54%	-353.32%	-2.63%
Profit Margin	8.97%	-181216.67%	-2635.41%	-367.65%	-5.97%
Free Cash Flow Margin	14.57%	-198136.67%	-3060.56%	-319.94%	50.86%
EBITDA	-3	-67.45	-34.43	-19.24	-0.46
EBITDA Margin	-3.37%	-	-	-	-2.60%
D&A For EBITDA	0.08	0.07	0.03	0.21	0.01
EBIT	-3.08	-67.52	-34.46	-19.45	-0.47
EBIT Margin	-3.46%	-	-	-	-2.63%
Effective Tax Rate	3.48%	-	-	-	-
Revenue as Reported	89.15	0.03	-	-	17.84

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q